Welcome!

News Feed Item

Orphan Diseases Partnering Terms and Agreements

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Orphan Diseases Partnering Terms and Agreements

https://www.reportbuyer.com/product/2043441/Orphan-Diseases-Partnering-Terms-and-Agreements.html

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in orphan diseases partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Orphan diseases partnering contract documents
Top orphan diseases deals by value

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter orphan diseases partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan diseases technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 90 links to online copies of actual orphan diseases deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of orphan diseases dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in orphan diseases dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading orphan diseases deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most active bigpharma/bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapters 4 and 5 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of orphan diseases deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides comprehensive access to all orphan diseases deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive directory of all orphan diseases partnering deals by specific therapeutic indication announced since 2009. The chapter is organized by specific orphan diseases therapeutic indication. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all orphan diseases partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in orphan diseases partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan diseases technologies and products.

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in orphan diseases dealmaking

2.1. Introduction
2.2. Orphan diseases partnering over the years
2.3. Big pharma orphan diseases dealmaking activity
2.4. Big biotech orphan diseases dealmaking activity
2.5. Most active in orphan diseases partnering
2.6. Orphan diseases partnering by deal type
2.7. Orphan diseases partnering by industry sector
2.8. Orphan diseases partnering by stage of development
2.9. Orphan diseases partnering by technology type
2.10. Average deal terms for orphan diseases
2.10.1 Orphan diseases headline values
2.10.2 Orphan diseases upfront payments
2.10.3 Orphan diseases milestone payments
2.10.4 Orphan diseases royalty rates

Chapter 3 - Leading orphan diseases deals

3.1. Introduction
3.2. Top orphan diseases deals by value

Chapter 4 - Big pharma orphan diseases deals

4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma orphan diseases partnering company profiles
Dainippon Sumitomo
Galderma
GlaxoSmithKline
Grifols
Kyowa Hakko Kirin
Mitsubishi Tanabe
Novartis
Pfizer
Sanofi
Shire
Shire Human Genetic Therapies
Takeda
Teva

Chapter 5 - Big biotech orphan diseases deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech orphan diseases partnering company profiles
Acorda Therapeutics
Actelion
BioMarin Pharmaceuticals
Grifols
Ipsen
Isis Pharmaceuticals
Swedish Orphan Biovitrum
ViroPharma

Chapter 6 - Orphan diseases partnering contracts directory

6.1. Introduction

6.2. Company A-Z

Aradigm
Arbios Systems
BioMarin Pharmaceutical
Catalyst Pharmaceutical Partners
Cell Therapeutics
Chiesi Farmaceutici
Chroma Therapeutics
Edison Pharmaceuticals
EpiCept
Galderma
GlaxoSmithKline
GlycoMimetics
Grifols
Halozyme Therapeutics
HepaLife
Hyperion Therapeutics
Ikaria
Intellect Neurosciences
Isis Pharmaceuticals
Kyowa Hakko Kirin
Meda
NovaBay Pharmaceuticals
Orphan Therapeutics
Penwest Pharmaceuticals
Pfizer
S*Bio
Saint Louis University
Ucyclyd Pharma
Ultragenyx Pharmaceuticals
UniQure
Viropharma

6.3. By deal type

Asset purchase
Co-development
Collaborative R&D
Co-market
Development
Equity purchase
Licensing
Marketing
Option
Settlement
Supply

6.4. By stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

6.5. By technology type

Assays
Biological compounds
Biomaterials
Cell culture
Enabling technology
Gene therapy
Implant
Oligonucleotide
Peptides
RNA therapeutics
Screening
Small molecules
Stem cells

Chapter 7 - Orphan diseases dealmaking by therapeutic target

7.1. Introduction
7.2. Deals by therapeutic target
Orphan diseases

Appendices

Appendix 1 - Directory of orphan diseases deals by company A-Z 2009- Jan 2014
Appendix 2 - Directory of orphan diseases deals by deal type 2009- Jan 2014
Appendix 3 - Directory of orphan diseases deals by stage of development 2009-Jan 2014
Appendix 4 - Directory of orphan diseases deals by technology type 2009- Jan 2014
Appendix 5 - Partnering resource center

Online partnering
Partnering events
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Therapy Reports

Table of figures

Figure 1: Orphan diseases partnering since 2009
Figure 2: Big pharma - top 50 - Orphan diseases deals 2009 to 2014
Figure 3: Big pharma orphan diseases deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - Orphan diseases deals 2009 to Jan 2014
Figure 5: Big biotech orphan diseases deal frequency - 2009 to 2014
Figure 6: Active orphan diseases dealmaking activity- 2009 to 2014
Figure 7: Orphan diseases partnering by deal type since 2009
Figure 8: Orphan diseases partnering by industry sector since 2009
Figure 9: Orphan diseases partnering by stage of development since 2009
Figure 10: Orphan diseases partnering by technology type since 2009
Figure 11: Orphan diseases deals with a headline value
Figure 12: Orphan diseases deal headline value distribution, US$million - discovery stage
Figure 13: Orphan diseases deal headline value distribution, US$million - preclinical stage
Figure 14: Orphan diseases deal headline value distribution, US$million - phase I stage
Figure 15: Orphan diseases deal headline value distribution, US$million - phase II stage
Figure 16: Orphan diseases deal headline value distribution, US$million - phase III stage
Figure 17: Orphan diseases deal headline value distribution, US$million - regulatory stage
Figure 18: Orphan diseases deal headline value distribution, US$million - marketed stage
Figure 19: Summary median headline value by stage of development, 2009-2014
Figure 20 Orphan diseases deals with upfront payment values
Figure 21: Orphan diseases deal upfront payment distribution, US$million - discovery stage
Figure 22: Orphan diseases deal upfront payment distribution, US$million - preclinical stage
Figure 23: Orphan diseases deal upfront payment distribution, US$million - phase I stage
Figure 24: Orphan diseases deal upfront payment distribution, US$million - phase II stage
Figure 25: Orphan diseases deal upfront payment distribution, US$million - phase III stage
Figure 26: Orphan diseases deal upfront payment distribution, US$million - regulatory stage
Figure 27: Orphan diseases deal upfront payment distribution, US$million - marketed stage
Figure 28: Summary median upfront payments by stage of development, 2009-2014
Figure 29: Orphan diseases deals with milestone payments
Figure 30: Orphan diseases deal milestone distribution, US$million - discovery stage
Figure 31: Orphan diseases deal milestone distribution, US$million - preclinical stage
Figure 32: Orphan diseases deal milestone distribution, US$million - phase I stage
Figure 33: Orphan diseases deal milestone distribution, US$million - phase II stage
Figure 34: Orphan diseases deal milestone distribution, US$million - phase III stage
Figure 35: Orphan diseases deal milestone distribution, US$million - regulatory stage
Figure 36: Orphan diseases deal milestone distribution, US$million - marketed stage
Figure 37: Orphan diseases deals with royalty rates, %
Figure 38: Orphan diseases deal royalty rate distribution, US$million - discovery stage
Figure 39: Orphan diseases deal royalty rate distribution, US$million - preclinical stage
Figure 40: Orphan diseases deal royalty rate distribution, US$million - phase I stage
Figure 41: Orphan diseases deal royalty rate distribution, US$million - phase II stage
Figure 42: Orphan diseases deal royalty rate distribution, US$million - phase III stage
Figure 43: Orphan diseases deal royalty rate distribution, US$million - regulatory stage
Figure 44: Orphan diseases deal royalty rate distribution, US$million - marketed stage
Figure 45: Summary median royalty rate by stage of development, 2009-2014
Figure 46: Top orphan diseases deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

Read the full report:
Orphan Diseases Partnering Terms and Agreements

https://www.reportbuyer.com/product/2043441/Orphan-Diseases-Partnering-Terms-and-Agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, described how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launching ...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone in...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, discussed how given the magnitude of today's application ...
The “Digital Era” is forcing us to engage with new methods to build, operate and maintain applications. This transformation also implies an evolution to more and more intelligent applications to better engage with the customers, while creating significant market differentiators. In both cases, the cloud has become a key enabler to embrace this digital revolution. So, moving to the cloud is no longer the question; the new questions are HOW and WHEN. To make this equation even more complex, most ...
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: imple...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...